Year Founded
2011
Ownership
Private
Employees
~50
Therapeutic Areas
Women's HealthOncology
Stage
Commercial
Modalities
Small molecule

Sprout Pharmaceuticals General Information

Company markets flibanserin (Addyi) for premenopausal women with HSDD in US and pre/postmenopausal women in Canada. Recent positive interim results in breast cancer patients with low libido.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Raleigh, North Carolina
United States

Drug Pipeline

flibanserin
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Sprout Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Valeant (historical), Bausch Health (historical)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Sprout Pharmaceuticals Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Sprout Pharmaceuticals's complete valuation and funding history, request access »

Sprout Pharmaceuticals Investors

Paycheck Protection Program
Investor Type: Venture Capital
Holding: Minority
Bausch Health
Investor Type: Venture Capital
Holding: Minority
Timberline Venture Capital Investments
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »